Comparative Pharmacology
Head-to-head clinical analysis: HYPAQUE versus HYPAQUE CYSTO.
Peer-Reviewed Evidence
Head-to-head clinical analysis: HYPAQUE versus HYPAQUE CYSTO.
HYPAQUE vs HYPAQUE-CYSTO
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Hypaque (diatrizoate sodium/diatrizoate meglumine) is an ionic, high-osmolar iodinated contrast agent. It attenuates X-rays by increasing the atomic density in tissues, providing radiographic contrast. It is not pharmacologically active but may cause physiological effects due to hyperosmolality.
HYPAQUE-CYSTO (diatrizoate meglumine) is a radiopaque contrast agent that absorbs x-rays, providing contrast in radiographic imaging. It acts as an iodinated contrast medium.
Intravenous: 50-300 mL of 30-60% solution depending on procedure; maximum 5 mL/kg. Intra-arterial: 5-80 mL per injection. Intrathecal: Not recommended due to neurotoxicity.
Intravesical instillation: 100-300 mL of 30% solution for retrograde cystourethrography; single administration.
None Documented
None Documented
The terminal elimination half-life is approximately 1-2 hours in patients with normal renal function. In renal impairment, half-life is prolonged and may exceed 20 hours in severe cases, requiring dose adjustment.
Terminal elimination half-life: 1.5–2.5 hours (normal renal function). Prolonged in renal impairment.
The drug is excreted unchanged primarily by the kidneys via glomerular filtration. Renal excretion accounts for >95% of elimination; biliary/fecal excretion is negligible (<5%).
Renal excretion via glomerular filtration: >95% unchanged within 24 hours. Fecal excretion: <5%.
Category C
Category C
Radiocontrast Agent
Radiocontrast Agent